Panxeon Blood Test Detects Early Pancreatic Cancer with 87% Accuracy
Published · Updated
AI-generated summary of the coverage listed below: A new blood test called Panxeon, developed by a company that also works with Grail, has shown promising results in clinical trials for detecting early-stage pancreatic cancer. The test correctly identified 87 percent of early cancers and detected precancerous conditions 64 percent of the time, potentially allowing earlier treatment and improving survival rates. The findings are being reviewed by the U.S. Food and Drug Administration as part of the test’s approval process.
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
Who is covering this story
- Center (2): Hindustan Times, Mid-Day
Sources
- A Grail Cancer Test for the FDA — Hindustan Times (center)
- Test PANXEON detects pancreatic cancer before it’s too late — Mid-Day (center)